Document is current
Any future updates will be listed below
-
Authors
Stas, Daan
Vandamme, Timon
Roeyen, Geert
Reynders, Dries
Demey, Wim
Stellamans, Karin
Bussels, Barbara
Hutsebaut, Isabel
Maurissen, Isabelle
Bouchart, Christelle
Berbée, Maaike
Lallemand, François
Poels, Hélène
Thomas, Melissa
Cuyle, Pieter-Jan
Bulens, Philippe
Verboven, Katleen
Martens, Michel
Weytjens, Reinhilde
Joye, Ines
-
Funding
Funding for this research was provided by:
Kom op tegen Kanker
Naslund Medical AB
- License Information
-
More Information
Article History
Received: 5 September 2025
Accepted: 12 September 2025
First Online: 30 October 2025
Declarations
:
: The study protocol has been approved by the central Ethics Committee of the University Hospital Antwerp (Reference ID 5500 -Edge 002715 - BUN B3002023000168 - dated April 8 2024). The study has been approved by each participating institution’s Institutional Review Board.
: Not applicable.
: TV reports consultancy, advisory roles, honoraria from AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Elmedix, Ipsen, MyNeoTx, SERB, Novartis, Roche, Sirtex, Servier. Research funding (institutional) from Ipsen and Novartis; support for travel/accomodation from Ipsen, AstraZeneca, Roche and Servier. The other authors declare that they have no conflicts of interest to disclose.
